Anti-Cytokeratin 1 antibody (ab93652)

Overview

  • Product nameAnti-Cytokeratin 1 antibody
    See all Cytokeratin 1 primary antibodies
  • Description
    Rabbit polyclonal to Cytokeratin 1
  • Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human Cytokeratin 1 (internal sequence).
    Database link: NM_006121

  • Positive control
    • WB: Fetal skin lysate IHC-P: Skin tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab93652 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF
WB
IHC-P
  • Application notesIHC-P: 1/100 - 1/500.
    WB: 1/200 - 1/1000. Predicted molecular weight: 66 kDa.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMay regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (RACK1/GNB2L1).
    • Tissue specificityThe source of this protein is neonatal foreskin. The 67-kDa type II keratins are expressed in terminally differentiating epidermis.
    • Involvement in diseaseDefects in KRT1 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
      Defects in KRT1 are the cause of ichthyosis hystrix Curth-Macklin type (IHCM) [MIM:146590]. IHCM is a genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks.
      Defects in KRT1 are a cause of palmoplantar keratoderma non-epidermolytic (NEPPK) [MIM:600962]. NEPKK is a dermatological disorder characterized by focal palmoplantar keratoderma with oral, genital, and follicular lesions.
      Defects in KRT1 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
      Defects in KRT1 are the cause of palmoplantar keratoderma striate type 3 (SPPK3) [MIM:607654]; also known as keratosis palmoplantaris striata III. SPPK3 is a dermatological disorder affecting palm and sole skin where stratum corneum and epidermal layers are thickened. There is no involvement of non-palmoplantar skin, and both hair and nails are normal.
    • Sequence similaritiesBelongs to the intermediate filament family.
    • Post-translational
      modifications
      Undergoes deimination of some arginine residues (citrullination).
    • Cellular localizationCell membrane. Located on plasma membrane of neuroblastoma NMB7 cells.
    • Information by UniProt
    • Database links
    • Alternative names
      • 67 kDa cytokeratin antibody
      • CK-1 antibody
      • CK1 antibody
      • Cytokeratin-1 antibody
      • Cytokeratin1 antibody
      • EHK antibody
      • EHK1 antibody
      • Epidermolytic hyperkeratosis 1 antibody
      • EPPK antibody
      • Hair alpha protein antibody
      • K1 antibody
      • K2C1_HUMAN antibody
      • Keratin antibody
      • Keratin type II cytoskeletal 1 antibody
      • Keratin-1 antibody
      • Keratin1 antibody
      • KRT 1 antibody
      • Krt1 antibody
      • KRT1A antibody
      • NEPPK antibody
      • type II cytoskeletal 1 antibody
      • Type II keratin Kb1 antibody
      • Type-II keratin Kb1 antibody
      see all

    Anti-Cytokeratin 1 antibody images

    • ab14404 staining Cytokeratin 1 in Human LNCaP, prostate cancer cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with formaldehyde and blocked with 1% Donkey serum for 1 hour at 22°C. Samples were incubated with primary antibody (1/100 in 1% Donkey serum in PBST) for 1 hour at 22°C. A DyLight® 594-conjugated Donkey anti-rabbit IgG polyclonal (1/200) was used as the secondary antibody. Red - cytokeratin 1, Green - Golgi marker ST3Gal1, Blue - nucleus (DAPI). 

      See Abreview

    • Anti-Cytokeratin 1 antibody (ab93652) at 1/500 dilution + fetal skin lysate

      Predicted band size : 66 kDa
    • ab93652, at a 1/100 dilution, staining Cytokeratin 1 in the membrane of formalin fixed, paraffin embedded skin tissue section by Immunohistochemistry.

    References for Anti-Cytokeratin 1 antibody (ab93652)

    ab93652 has not yet been referenced specifically in any publications.

    Product Wall

    I am sorry that this antibody did not perform as stated on the datasheet. If payment has already been made on the original order and you wish to receive a refund, please ask your purchasing department to contact our accounting department so that we may...

    Read More
    Application Western blot
    Loading amount 35 µg
    Gel Running Conditions Reduced Denaturing (12% SDS-PAGE)
    Sample Rat Cell lysate - other (Rat hepatocytes plasma membrane fraction)
    Specification Rat hepatocytes plasma membrane fraction
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
    Username

    Dr. Armen Petrosyan

    Verified customer

    Submitted Oct 28 2014

    Application Immunocytochemistry/ Immunofluorescence
    Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C
    Sample Human Cell (LNCaP, prostate cancer cells)
    Specification LNCaP, prostate cancer cells
    Permeabilization No
    Fixative Formaldehyde
    Username

    Dr. Armen Petrosyan

    Verified customer

    Submitted Oct 17 2013

    Application Western blot
    Loading amount 30 µg
    Gel Running Conditions Reduced Denaturing (4-15% gradient polyacrilamide gel)
    Sample Human Cell lysate - whole cell (LNCaP, prostate cancer cells)
    Specification LNCaP, prostate cancer cells
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
    Username

    Dr. Armen Petrosyan

    Verified customer

    Submitted Oct 17 2013

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"